These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27826993)

  • 21. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor.
    Jones R; Patrikios T
    Int J Clin Pract; 2008 Dec; 62(12):1844-50. PubMed ID: 19166433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
    van der Velden AW; de Wit NJ; Quartero AO; Grobbee DE; Numans ME
    Digestion; 2013; 87(2):85-90. PubMed ID: 23364219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care.
    Jones R; Coyne K; Wiklund I
    Aliment Pharmacol Ther; 2007 Jun; 25(12):1451-9. PubMed ID: 17539985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of a symptom diary for patients with gastro-oesophageal reflux disease.
    Puhan MA; Guyatt GH; Armstrong D; Wiklund I; Fallone CA; Heels-Ansdell D; Degl'Innocenti A; Veldhuyzen van Zanten SJ; Tanser L; Barkun AN; Chiba N; Austin P; El-Dika S; Schünemann HJ
    Aliment Pharmacol Ther; 2006 Feb; 23(4):531-41. PubMed ID: 16441474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signal detection theory approach to gastroesophageal reflux disease: a new method for symptom analysis of impedance-pH data.
    Giral A; Kurt R; Yeğin EG; Yeğin K
    Dis Esophagus; 2014 Apr; 27(3):206-13. PubMed ID: 23795569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease.
    Bardhan KD; Stanghellini V; Armstrong D; Berghöfer P; Gatz G; Mönnikes H
    Aliment Pharmacol Ther; 2004 Oct; 20(8):891-8. PubMed ID: 15479361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.
    Heading RC; Mönnikes H; Tholen A; Schmitt H
    BMC Gastroenterol; 2011 May; 11():52. PubMed ID: 21569313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of heartburn not responding to proton pump inhibitors.
    Fass R; Sifrim D
    Gut; 2009 Feb; 58(2):295-309. PubMed ID: 19136523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Daily versus Weekly Recording of Gastroesophageal Reflux Disease Symptoms in Patients with a Partial Response to Proton Pump Inhibitor Therapy.
    Rydén A; Leavy OC; Halling K; Stone AA
    Value Health; 2016; 19(6):829-833. PubMed ID: 27712711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease.
    Zerbib F; Bruley des Varannes S; Roman S; Tutuian R; Galmiche JP; Mion F; Tack J; Malfertheiner P; Keywood C
    Aliment Pharmacol Ther; 2011 Apr; 33(8):911-21. PubMed ID: 21320138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn.
    Zerbib F; Sacher-Huvelin S; Coron E; Coffin B; Melchior C; Ponchon T; Cholet F; Chabrun E; Vavasseur F; Gorbatchef C; Zalar A; Mion F; Robaszkiewicz M; Le Rhun M; Leroy M; Paul Galmiche J; Bruley des Varannes S
    Aliment Pharmacol Ther; 2020 Aug; 52(4):637-645. PubMed ID: 32656869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. pH-Impedance Findings and proton pump inhibitors-responsiveness in patients with typical gastroesophageal reflux disease symptoms in a large single-center Italian series.
    Vailati C; Mazzoleni G; Testoni PA; Passaretti S
    J Clin Gastroenterol; 2014 Aug; 48(7):613-9. PubMed ID: 24326754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between symptom response and oesophageal acid exposure after medical and surgical treatment for gastro-oesophageal reflux disease.
    Jenkinson AD; Kadirkamanathan SS; Scott SM; Yazaki E; Evans DF
    Br J Surg; 2004 Nov; 91(11):1460-5. PubMed ID: 15386326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors.
    Zerbib F; Duriez A; Roman S; Capdepont M; Mion F
    Gut; 2008 Feb; 57(2):156-60. PubMed ID: 17951358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the reflux disease questionnaire useful for identifying GERD according to the Montreal definition?
    Rey E; Barceló M; Zapardiel J; Sobreviela E; Muñoz M; Díaz-Rubio M
    BMC Gastroenterol; 2014 Jan; 14():17. PubMed ID: 24450939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
    Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
    Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
    Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
    Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.